Organisation paid for research Program year 2025 Source: CMS Open Payments

HEA Clinic

Neither a doctor nor a teaching hospital

Research payments

$310,009

62 payments

Through program year 2025, HEA Clinic is reported as receiving $310,009 in research payments, across 62 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$162,569	27
2024	Research	$43,590	8
2023	Research	$13,640	9
2022	Research	$90,210	18

Breakdown

Who paid Research payments · program years 2022–2025

Glaukos Corporation $310,009 62 payments

Studies the money was for Research payments · program years 2022–2025

Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension $106,544 20 payments
A Prospective, Multicenter Study of the Glaukos Istent Infinite Trabecular Micro-Bypass System Model Is3 in Subjects With Mild to Moderate Primary Open-Angle Glaucoma $59,195 8 payments
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone $39,920 6 payments
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $10,640 7 payments
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6% and 8% BID for the Treatment of Presbyopia $1,500 1 payment
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6% and 8% BID for the Treatment of Signs and Symptoms of Dry Eye Disease $1,500 1 payment
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.